CEDARS-SINAI MEDICAL CENTER

CLINICAL CARE:CEDARS-SINAI IS RENOWNED FOR A PIONEERING AND CREATIVE SPIRIT THAT DRIVES CHANGE. THIS YEAR, THAT ENDLESS QUEST FOR INNOVATION FUELED BREAKTHROUGHS AND INSPIRED NEW GENERATIONS OF HEALTHCARE LEADERS. WITH A GROWING NETWORK THAT NOW EXTENDS THROUGHOUT LOS ANGELES AND FAR BEYOND, CEDARS-SINAI'S IMPACT CONTINUES TO BROADEN EVEN AS IT REMAINS DEEPLY ROOTED IN THIS COMMUNITY. (SEE SCHEDULE O FOR CONTINUATION)(CONTINUED)IN FISCAL YEAR 2024, CEDARS-SINAI MEDICAL CENTER REPORTED 296,716 INPATIENT DAYS AND 938,702 OUTPATIENT VISITS. OTHER VOLUME MEASURES INCLUDE 45,147 INPATIENT ADMISSIONS , AND 85,709 EMERGENCY DEPARTMENT VISITS . AS ONE OF THE LARGEST ACADEMIC MEDICAL CENTERS IN THE WESTERN UNITED STATES, CEDARS-SINAI PROVIDES MANY HIGHLY SPECIALIZED SERVICES THAT ARE NOT AVAILABLE AT MOST OTHER HOSPITALS, AND WHICH REQUIRE A SIGNIFICANT INFRASTRUCTURE OF TECHNOLOGY AND EXPERT STAFFING. SURGEONS AT THE CEDARS-SINAI SPINE CENTER PIONEERED A MINIMALLY INVASIVE SPINE PROCEDURE TO ELIMINATE DEBILITATING PAIN WITHOUT CAUSING TRAUMA TO THE SPINE, HELPING PATIENTS RECOVER QUICKER. THE AORTIC SURVEILLANCE CLINIC OFFERS EVALUATION AND MONITORING OF PATIENTS WITH ENLARGED AORTAS, OR AORTIC ANEURYSMS, WHO MAY NOT NEED SURGERY. THE CLINIC IS THE NEWEST OFFERING FROM THE DEDICATED AORTIC PROGRAM IN THE SMIDT HEART INSTITUTE AT CEDARS-SINAI. PHYSICIANS IN THE SMIDT HEART INSTITUTE AT CEDARS-SINAI HAVE PIONEERED A CATHETER-BASED APPROACH TO TREAT PATIENTS WITH TRICUSPID VALVE DISEASE, FOLLOWING U.S. FOOD AND DRUG ADMINISTRATION APPROVAL, AND HAVE PERFORMED MORE THAN 100 MINIMALLY INVASIVE VALVE REPLACEMENTS. WOMEN WITH COMPLEX PREGNANCIES OR WHO ENCOUNTER COMPLICATIONS THAT REQUIRE SPECIALIZED CARE FOR THEMSELVES OR THEIR UNBORN CHILD RECEIVE EXPERT CARE THROUGH THE MEDICAL CENTER'S HIGH-RISK PERINATAL PROGRAM.CEDARS-SINAI IS DEVELOPING AN ALL-INCLUSIVE HUB FOR CLINICAL TRIALS THAT ENCOMPASSES THERAPEUTIC DEVELOPMENT, FUNDING, TESTING AND DATA MANAGEMENT TO REACH PATIENTS WITH POTENTIAL BREAKTHROUGHS MORE QUICKLY, EFFICIENTLY, AND SAFELY.

RESEARCH:USING MOLECULAR TWIN TECHNOLOGY-A UNIQUE PRECISION MEDICINE AND ARTIFICIAL INTELLIGENCE TOOL DEVELOPED AT CEDARS-SINAI-CEDARS-SINAI CANCER INVESTIGATORS IDENTIFIED BIOMARKERS FOR PREDICTING PANCREATIC CANCER SURVIVAL MORE ACCURATELY THAN CURRENT STANDARDS OF TESTING. THEIR RESEARCH, PUBLISHED IN NATURE CANCER, DEMONSTRATES THE VIABILITY OF A TOOL THAT CAN BE USED TO STUDY ANY TUMOR TYPE AND COULD ONE DAY GUIDE AND IMPROVE TREATMENT FOR ALL CANCER PATIENTS.(SEE SCHEDULE O FOR CONTINUATION)(CONTINUED)THREE NEW STUDIES BY CEDARS-SINAI INVESTIGATORS HAVE DEEPENED ITS KNOWLEDGE ABOUT THE EYE-BRAIN CONNECTION, WHICH COULD ENABLE EARLIER DIAGNOSIS OF ALZHEIMER'S DISEASE-A KEY FACTOR IN DEVELOPING EFFECTIVE TREATMENTS.CEDARS-SINAI GUERIN CHILDREN'S NEWLY ESTABLISHED DEVELOPMENTAL BIOLOGY AND REGENERATIVE PEDIATRICS CENTER BRINGS TOGETHER INVESTIGATORS STUDYING CELLULAR PROCESSES IN DEVELOPMENT AND RENEWAL.CEDARS-SINAI RESEARCHERS HAVE DISCOVERED WHICH BRAIN CELLS ARE RESPONSIBLE FOR THE STORAGE OF INFORMATION IN SHORT-TERM MEMORY, WHICH IS VITAL FOR PERFORMING TASKS AND MAKING DECISIONS. THE TEAM ALSO DEFINED THE ROLE OF THESE CELLS IN RETAINING A MEMORY ONCE IT IS FORMED, THE DISRUPTION OF WHICH IS ASSOCIATED WITH CONDITIONS SUCH AS ALZHEIMER'S DISEASE AND ATTENTION-DEFICIT/HYPERACTIVITY DISORDER. UNDERSTANDING HOW WORKING MEMORY IS CONTROLLED WILL BE FUNDAMENTAL TO DEVELOPING NEW TREATMENTS FOR THESE AND OTHER NEUROLOGICAL CONDITIONS.